The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful.
Download our white paper for insights on:
- Optimizing formulation development and tech transfer to ensure successful biologics production
- Benefits of partnering with a CDMO with end-to-end services from drug product formulation to fill-finish; which mitigates risk, saves time and reduces cost
- Learnings and solutions from three real-world case studies
